1. Home
  2. OSUR vs SLN Comparison

OSUR vs SLN Comparison

Compare OSUR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$2.91

Market Cap

214.1M

Sector

Health Care

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.20

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
SLN
Founded
2000
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.1M
236.2M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
OSUR
SLN
Price
$2.91
$6.20
Analyst Decision
Hold
Buy
Analyst Count
2
5
Target Price
$3.00
$42.60
AVG Volume (30 Days)
484.0K
255.6K
Earning Date
05-06-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,064,000.00
N/A
Revenue This Year
$4.48
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$1.97
52 Week High
$4.22
$7.91

Technical Indicators

Market Signals
Indicator
OSUR
SLN
Relative Strength Index (RSI) 47.96 52.83
Support Level $2.69 $5.79
Resistance Level $2.99 $7.40
Average True Range (ATR) 0.18 0.69
MACD -0.03 -0.00
Stochastic Oscillator 19.40 42.71

Price Performance

Historical Comparison
OSUR
SLN

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: